Phibro Animal Health vs Royalty Pharma
Royalty Pharma is the larger business, with $2.38bn of revenue in fiscal 2025 against $1.52bn for Phibro Animal Health (1.6 times as much). Phibro Animal Health grew faster (17.1% against 5.1%). Royalty Pharma kept more of each dollar of sales as profit: a net margin of 32.4% against 6.6%.
| Latest fiscal year | Phibro Animal HealthPAHC, 2026 | Royalty PharmaRPRX, 2025 |
|---|---|---|
| Revenue | $1.52bn | $2.38bn |
| Revenue growth | 17.1% | 5.1% |
| Net income | $99.7m | $771m |
| Operating margin | — | 65.6% |
| Net margin | 6.6% | 32.4% |
| Return on equity | 29.7% | 7.7% |
| Free cash flow | $9.9m | — |
| Cash | $61.4m | $619m |
| Total debt | $738m | $8.95bn |
| Debt to equity | — | 92.1% |
| Dividend per share | $0.48 | — |
| Dividend yield | 1.2% | — |
| Share buybacks | — | $1.23bn |
| Employees | 2,605 | 100 |
| Market value | $1.53bn | $36.94bn |
| Price vs our value range | Within our value range | Within our value range |
| Moat score | 49 (Moderate) | — |
| Insider trades, 12 months | 1 buys, 109 sales | 0 buys, 74 sales |